August 29th 2024
At T0, skin layers appeared normal, and at T1, filler deposits were clearly visible as hyporeflective areas.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Redistribute facial fat for rejuvenation
October 1st 2001New Haven, Conn. - Fat redistribution is the primary reason formorphologic alterations in the aging face, said Lisa M. Donofrio, M.D. Torestore the youthful appearance of most patients, fat augmentation thatrebuilds the facial planes of youth must be the main objective of any rejuvenationprocedure.
Composite nail grafts used for reconstruction
October 1st 2001Springfield, Ill. - A pivotal study undertaken at the Institutefor Plastic and Reconstructive Surgery at Southern Illinois University isthe first to evaluate a large series of patients receiving free compositematrix grafts in various conditions.
Combination therapy may be answer for CTCL
October 1st 2001Anaheim, Calif. - Combination therapy with biological responsemodifiers and careful and regular reassessment of refractory patients areof paramount importance in the effective treatment of cutaneous T-cell lymphoma,according to Carmela C. Vittorio, M.D.
Retinoic acid metabolism inhibitor causes less irritation
October 1st 2001Washington - A series of cutaneous pharmacology studies conductedwith a selective retinoic acid metabolism inhibitor suggest this novel compoundhas the potential for treating a variety of retinoid-responsive dermatologicdiseases but with the advantage of causing less irritation compared to retinoicacid, Gerard J. Gendimenico, Ph.D., said at the Society for InvestigativeDermatology meeting.